Neuropsychiatric Symptoms and Quality of Life in Spanish Alzheimer's Disease Patients During COVID-19 Lockdown
Piñol Ripoll, Gerard
MetadataShow full item record
Background and purpose: The COVID epidemic is affecting individuals worldwide, and Alzheimer's disease (AD) and amnesic mild cognitive impairment (MCI) patients are at risk due to their characteristics and age. We analysed the impact of the pandemic on these patients' neuropsychiatric symptoms and their
quality of life after five weeks of lockdown in Spain. Methods: We tested 40 subjects with a diagnosis of MCI (20) or mild AD (20) from the Cognitive Stimulation Program of Cognitive Disorders Unit. All patients had undergone a previous evaluation during the month before the lockdown, and they were re-evaluated after 5 weeks of lockdown. The Neuropsychiatric Inventory (NPI) and EuroQol-5D were used to evaluate the neuropsychiatric symptoms and quality of life of patients and caregivers. Results: The total baseline NPI score was 33.75 (22.28) vs 39.05 (27.96) after confinement (p=0.028). The most frequent neuropsychiatric symptoms affected were apathy (4.15 (3.78) vs 5.75 (4.02); p=0.002) and anxiety (3.95 (3.73) vs 5.30 (4.01); p=0.006) in MCI patients and apathy (2.35 (2.70) vs 3.75 (3.78); p=0.036), agitation (0.45 (1.14) vs 1.50 (2.66); p=0.029) and aberrant motor behaviour (1.25 (2.86) vs 2.00 (2.93); p=0.044) in AD patients. We did not observe differences in EuroQol-5D scores during the reevaluation. Approximately 30% of patients and 40% of caregivers reported a worsening of their health status during confinement. Conclusions: We have demonstrated the worsening of neuropsychiatric symptoms in patients with AD and MCI during 5 weeks of lockdown, with agitation, apathy and aberrant motor activity being the most affected symptoms.
Is part ofEuropean Journal of Neurology, 2020, In press
Showing items related by title, author, creator and subject.
Study of community-living Alzheimer’s patients’ adherence to the Mediterranean diet and risks of malnutrition at different disease stages Rocaspana-Garcia, Mariona; Blanco Blanco, Joan; Arias-Pastor, Alfonso; Gea Sánchez, Montserrat; Piñol Ripoll, Gerard (PeerJ, 2018)Alzheimer’s disease (AD) is a neurodegenerative disease that is characterized by deficits in episodic memory. It is the most common form of dementia and affects 50–70% of patients with cognitive impairments over the age ...
Alzheimer’s disease mutant mice exhibit reduced brain tissue stiffness compared to wild-type mice in both normoxia and following intermittent hypoxia mimicking sleep apnea Menal Castellote, Maria José; Jorba, Ignasi; Torres, Marta; Montserrat i Capdevila, Josep; Gozal, David; Colell, Anna; Piñol Ripoll, Gerard; Navajas, Daniel; Almendros, Isaac; Farré, Ramon (Frontiers Media, 2018)Background: Evidence from patients and animal models suggests that obstructive sleep apnea (OSA) may increase the risk of Alzheimer’s disease (AD) and that AD is associated with reduced brain tissue stiffness. Aim: To ...
proBDNF is modified by advanced glycation end products in Alzheimer’s disease and causes neuronal apoptosis by inducing p75 neurotrophin receptor processing Fleitas Pérez, Catherine; Piñol Ripoll, Gerard; Marfull Oromí, Pau; Rocandio, Daniel; Ferrer, Isidre; Rampon, Claire; Egea Navarro, Joaquim; Espinet Mestre, Carme (BMC, 2018)Alzheimer disease (AD) is a complex pathology related to multiple causes including oxidative stress. Brain-derived neurotrophic factor (BDNF) is a neutrotrophic factor essential for the survival and differentiation of ...